JPWO2023154730A5 - - Google Patents

Info

Publication number
JPWO2023154730A5
JPWO2023154730A5 JP2024547227A JP2024547227A JPWO2023154730A5 JP WO2023154730 A5 JPWO2023154730 A5 JP WO2023154730A5 JP 2024547227 A JP2024547227 A JP 2024547227A JP 2024547227 A JP2024547227 A JP 2024547227A JP WO2023154730 A5 JPWO2023154730 A5 JP WO2023154730A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506143A5 (https=
JP2025506143A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062185 external-priority patent/WO2023154730A2/en
Publication of JP2025506143A publication Critical patent/JP2025506143A/ja
Publication of JP2025506143A5 publication Critical patent/JP2025506143A5/ja
Publication of JPWO2023154730A5 publication Critical patent/JPWO2023154730A5/ja
Pending legal-status Critical Current

Links

JP2024547227A 2022-02-09 2023-02-08 多重特異性結合性作用剤およびその使用 Pending JP2025506143A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263308485P 2022-02-09 2022-02-09
US63/308,485 2022-02-09
US202263425960P 2022-11-16 2022-11-16
US63/425,960 2022-11-16
PCT/US2023/062185 WO2023154730A2 (en) 2022-02-09 2023-02-08 Multispecific binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2025506143A JP2025506143A (ja) 2025-03-07
JP2025506143A5 JP2025506143A5 (https=) 2026-02-13
JPWO2023154730A5 true JPWO2023154730A5 (https=) 2026-02-13

Family

ID=87565080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547227A Pending JP2025506143A (ja) 2022-02-09 2023-02-08 多重特異性結合性作用剤およびその使用

Country Status (6)

Country Link
US (1) US20250197502A1 (https=)
EP (1) EP4475886A4 (https=)
JP (1) JP2025506143A (https=)
AU (1) AU2023219697A1 (https=)
CA (1) CA3243802A1 (https=)
WO (1) WO2023154730A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof
WO2025133389A1 (en) * 2023-12-22 2025-06-26 Numab Therapeutics AG Antibody binding domains having specificity for lilrb2
EP4574844A1 (en) * 2023-12-22 2025-06-25 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
KR20210096612A (ko) * 2018-10-29 2021-08-05 티가티엑스, 인크. IgA 항체 구축물을 포함하는 조성물 및 방법
AU2021205440A1 (en) * 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof

Similar Documents

Publication Publication Date Title
JP2024150445A5 (https=)
JP2021503455A5 (https=)
JP2019507135A5 (https=)
JP2021510736A5 (https=)
JP2026041845A5 (https=)
JP2020533016A5 (https=)
JP2023089245A5 (https=)
JP2010509931A (ja) 新規抗増殖性化合物
JP2024001073A5 (https=)
JPWO2019141732A5 (https=)
JP2022513437A5 (https=)
WO2002072008A9 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
JPWO2023154730A5 (https=)
JPWO2020081928A5 (https=)
JPWO2020191342A5 (https=)
JPWO2022031710A5 (https=)
JPWO2020206033A5 (https=)
JPWO2021133723A5 (https=)
WO2023222135A1 (en) A method of treating solid tumor
JPWO2023028653A5 (https=)
JPWO2022031695A5 (https=)
TW202400662A (zh) 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途
JPWO2022240833A5 (https=)
JPWO2021092380A5 (https=)
CN119505001B (zh) 靶向cd22的全人源抗体及其应用